Valneva SE (NASDAQ:VALN) Short Interest Down 34.6% in January

Valneva SE (NASDAQ:VALN) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 15,900 shares, a drop of 34.6% from the December 31st total of 24,300 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 38,300 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Valneva in a research report on Friday.

Valneva Stock Performance

NASDAQ VALN traded up $0.52 during trading on Friday, hitting $5.77. 33,952 shares of the company’s stock traded hands, compared to its average volume of 49,515. The business has a 50 day moving average of $4.32 and a 200-day moving average of $5.72. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock has a market capitalization of $468.87 million, a price-to-earnings ratio of -44.50 and a beta of 1.93.

Institutional Investors Weigh In On Valneva

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA acquired a new stake in shares of Valneva SE (NASDAQ:VALN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.